Total Synthesis of Bryostatin 1: A Short Route

2011 ◽  
Vol 50 (38) ◽  
pp. 8786-8789 ◽  
Author(s):  
Soraya Manaviazar ◽  
Karl J. Hale
ChemInform ◽  
2012 ◽  
Vol 43 (5) ◽  
pp. no-no
Author(s):  
Soraya Manaviazar ◽  
Karl J. Hale

2020 ◽  
Vol 17 (7) ◽  
pp. 588-591
Author(s):  
Pingxuan Shao ◽  
Wei Lu ◽  
Lei Wang

A practical and concise total synthesis of tricyclic ketone 7 (CDE ring), a valuable intermediate for the synthesis of racemic camptothecin and analogs, was described (8 chemical steps and 29% overall yield). The synthesis starts with two inexpensive, readily available materials and is operationally simple to perform. It is worth mentioning that the reported protecting group-free synthesis, with advantages of a short route, would be helpful for the future development of industry-scale syntheses of camptothecin-family alkaloids.


2020 ◽  
Vol 21 (4) ◽  
pp. 1179
Author(s):  
Kazuma Murakami ◽  
Mayuko Yoshimura ◽  
Shota Nakagawa ◽  
Toshiaki Kume ◽  
Takayuki Kondo ◽  
...  

Amyloid β42 (Aβ42), a causative agent of Alzheimer’s disease (AD), is derived extracellularly from Aβ precursor protein (APP) following the latter’s cleavage by β-secretase, but not α-secretase. Protein kinase Cα (PKCα) activation is known to increase α-secretase activity, thereby suppressing Aβ production. Since Aβ42 oligomer formation causes potent neurotoxicity, APP modulation by PKC ligands is a promising strategy for AD treatment. Although bryostatin-1 (bryo-1) is a leading compound for this strategy, its limited natural availability and the difficulty of its total synthesis impedes further research. To address this limitation, Irie and colleagues have developed a new PKC activator with few side effects, 10-Me-Aplog-1, (1), which decreased Aβ42 in the conditioned medium of rat primary cerebral cortex cells. These results are associated with increased α-secretase but not PKCε-dependent Aβ-degrading enzyme. The amount of neuronal embryonic lethal abnormal vision (nELAV), a known β-secretase stabilizer, was reduced by treatment with 1. Notably, 1 prevented the formation of intracellular toxic oligomers. Furthermore, 1 suppressed toxic oligomerization within human iPS-derived neurons such as bryo-1. Given that 1 was not neurotoxic toward either cell line, these findings suggest that 1 is a potential drug lead for AD therapy.


2010 ◽  
Vol 49 (27) ◽  
pp. 4580-4584 ◽  
Author(s):  
Gary E. Keck ◽  
Yam B. Poudel ◽  
Arnab Rudra ◽  
Jeffrey C. Stephens ◽  
Noemi Kedei ◽  
...  

2010 ◽  
Vol 122 (27) ◽  
pp. 4684-4688 ◽  
Author(s):  
Gary E. Keck ◽  
Yam B. Poudel ◽  
Arnab Rudra ◽  
Jeffrey C. Stephens ◽  
Noemi Kedei ◽  
...  

2016 ◽  
Vol 79 (8) ◽  
pp. 2039-2044 ◽  
Author(s):  
Usein M. Dzhemilev ◽  
Vladimir A. D’yakonov ◽  
Regina A. Tuktarova ◽  
Lilya U. Dzhemileva ◽  
Svetlana R. Ishmukhametova ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document